TATTON study, set up in the back drop of acquired MET amplification associated with EGFR–TKI resistance offered explicit benefit with savolitinib in NSCLC patients without prior third-generation EGFR–TKI, while those who were administered with a prior third-generation EGFR–TKI had a relatively lower rate of response regardless of T790 status, possibly related to larger proportion of patients with ≥3 lines of treatment comprising the prior third-generation EGFR–TKI group (56.5% vs. 22.6% in partB2 + partD). This evidence concerns the gene EGFR and non-small cell lung carcinoma.